Why Rhythm Pharmaceuticals, Inc. (RYTM) stock moved
Rhythm Pharmaceuticals, Inc. (RYTM) shares fell 1.9% to $104.60 as of July 21, 2026, a modest decline from the prior close of $106.60. BestStocks flagged the session as a major change for RYTM. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for RYTM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RYTM fell 1.9% to $104.60
RYTM fell 1.9% in its latest session, moving from $106.60 to $104.60.
What it means for Rhythm Pharmaceuticals, Inc. investors
For Rhythm Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Rhythm Pharmaceuticals, Inc. (RYTM) moved +0.92% from $114.43 to $115.48 on 2026-07-09, reaching a new 30-day high; Rhythm Pharmaceuticals, Inc. (RYTM) moved +3.41% from $110.41 to $114.17 on 2026-07-02, reaching a new 30-day high. Weighing against that: Negative session, down 1.9%; Rhythm Pharmaceuticals, Inc. (RYTM) moved -3.28% from $109.69 to $106.09 on 2026-07-16. Wall Street's consensus price target sits at $141.33, implying +35.1% upside from $104.60. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
RYTM price reaction
RYTM last traded at $104.60, down $2.00 (-1.88%) from the previous close of $106.60. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $101.39 and $115.48, and it currently sits about 23% of the way up that band.
Bullish and bearish analyst opinions on Rhythm Pharmaceuticals, Inc. (RYTM)
The consensus analyst price target on Rhythm Pharmaceuticals, Inc. (RYTM) is $141.33, 35.1% above the recent $104.60. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RYTM line up.
The bullish case
- Wall Street's consensus price target of $141.33 implies +35.1% upside from $104.60.
- The Street's most bullish target is $155.00 (+48.2%).
- Rhythm Pharmaceuticals, Inc. (RYTM) moved +0.92% from $114.43 to $115.48 on 2026-07-09, reaching a new 30-day high.
The bearish case
- Negative session, down 1.9%.
- Rhythm Pharmaceuticals, Inc. (RYTM) moved -3.28% from $109.69 to $106.09 on 2026-07-16.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RYTM
Frequently asked questions about RYTM
Why did Rhythm Pharmaceuticals, Inc. (RYTM) stock move?
RYTM fell 1.9% to $104.60. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RYTM stock fall?
RYTM lost 1.88% ($2.00) versus the prior close of $106.60, last trading at $104.60 on 0.6× average volume.
When is Rhythm Pharmaceuticals, Inc.'s next earnings date?
RYTM's next earnings report is estimated for 2026-08-04 — about 14 days away.
What is the analyst price target for RYTM?
The consensus analyst price target for RYTM is $141.33, about 35.1% above the current $104.60. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks RYTM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RYTM-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for RYTM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.